MADISON,
Wis., Jan. 23, 2025 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer
Hospital and Institute has achieved a milestone with the completion
of treatment for 100 patients using the Tomo® C
Radiation Treatment Delivery System, a product built in
China through the CNNC-Accuray
joint venture. Shandong Cancer Hospital and Institute was the first
hospital in China to receive the
new Tomo C System which has already demonstrated its
value by expanding clinical capabilities and the opportunity to
offer potentially curative treatment to more people diagnosed with
cancer. This first cohort of Tomo C System treatments also
represent a milestone for Accuray which is focused on addressing
the broad needs of the underserved Chinese radiation therapy
market.
The number of new cancer cases in China is anticipated to increase by almost 47
percent in the coming years with about 7.1 million people expected
to be diagnosed in 2045, compared to an estimated 4.8 million
people in 20221. The data reinforces the importance of
advanced radiotherapy technology that enables the precise treatment
of the full spectrum of cancer cases clinical teams see in their
practice.
"We are proud to support the Shandong Cancer
Hospital and Institute team as they enhance their cancer treatment
options with the new Tomo C System. I am pleased that a wide range
of cancer types were successfully treated among these 100 patients
and that the fast speed of treatment is expected to meaningfully
increase capacity - enabling them to treat more patients per day,"
said Suzanne Winter, president and
CEO of Accuray.
Continued Ms. Winter, "The system was developed
to enable more clinicians in China
to offer fast, effective, personalized cancer care to their
patients. Its introduction expands our product portfolio in this
important region and reinforces our commitment to providing our
customers with the tools they need to offer the best care possible
to any patient they believe would benefit from radiotherapy."
Shandong Cancer Hospital and Institute, founded
in 1958, is a top center for cancer care, research, and prevention
in China. Serving over 400,000
patients annually, it offers advanced treatments and collaborates
with global leaders such as MD Anderson Cancer Center in
the United States. The hospital is
committed to innovation and excellence in cancer treatment.
"The introduction of the Tomo C Radiation
Treatment Delivery System, based on the helical
TomoTherapy® platform, is a significant milestone in
advancing precision radiotherapy for cancer patients," said Prof.
Yu, President of Shandong Cancer Hospital. "The TomoTherapy
platform has already demonstrated its transformative impact on
cancer treatment. With the Tomo C System we can treat an average of
95 patient treatment fractions per day, enabling our team to
provide innovative and effective care for more patients and
reaffirming our commitment to the "Healthy China Initiative." This
achievement sets a new benchmark for cancer care, propelling our
efforts to the next level."
The Tomo C System is designed to provide medical
care teams with greater certainty in the outcomes they achieve when
treating patients with radiotherapy. Each component of the
system – from helical imaging and delivery to advanced treatment
planning and centralized data management – is designed to work
seamlessly together to facilitate fast, ultra-precise
treatments while enabling more patients to receive care each
day.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Madison,
Wisconsin, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, X, and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations and goals
regarding the company's products, services and innovations,
including related to the Tomo C Radiation Treatment Delivery
System; expectations regarding the company's joint venture in
China; and patient experiences and
patient outcomes. These risks and uncertainties include, but are
not limited to, the effect of the current global economic
environment, including in connection to the COVID-19 pandemic, on
the operations of the company and those of its customers and
suppliers; the company's ability to achieve widespread market
acceptance of its products; the company's ability to develop new
products or improve existing products to meet customers' needs; the
company's ability to anticipate or keep pace with changes in the
marketplace and the direction of technological innovation and
customer demands; reliance on third party collaborators,
partnerships, strategic alliances and joint ventures; and such
other risks identified under the heading "Risk Factors" in the
company's Quarterly Report on Form 10-Q, filed with the Securities
and Exchange Commission (the "SEC") on November 6, 2024, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the
date the statements are made and are based on information available
to the company at the time those statements are made and/or
management's good faith belief as of that time with respect to
future events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors
should not put undue reliance on any forward-looking
statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
________________________
1International Agency for Research on Cancer, World
Health Organization.
https://gco.iarc.fr/tomorrow/en/dataviz/tables?populations=160
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-100-patient-treatment-regimens-completed-in-china-using-the-tomo-c-radiation-treatment-delivery-system-a-cnnc-accuray-joint-venture-product-302355700.html
SOURCE Accuray Incorporated
